Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

NCT05266196 is registered in ClinicalTrials.gov with Salarius Pharmaceuticals, LLC as lead sponsor.

NCT NCT05266196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Lead sponsor
Salarius Pharmaceuticals, LLC
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 15, 2022
Completion date
December 31, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiomatoid fibrous histiocytoma, clear cell sarcoma, desmoplastic small round cell tumor, ewing sarcoma, extraskeletal myxoid chondrosarcoma, low grade fibromyxoid sarcoma, myoepithelial tumor, myxoid liposarcoma, sclerosing epithelioid fibrosarcoma